Silence Therapeutics plc (SLN)
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
$11.18-0.04%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+81.1%
The outlook
Silence Therapeutics plc currently reads as bullish based on buy — 1.7 avg of 6 analysts, above its 50- & 200-day averages, 87% of the way from its 52-week low to high, avg target +161% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusBuy — 1.7 avg of 6 analysts
Price trendAbove its 50- & 200-day averages
52-week range87% of the way from its 52-week low to high
Price targetAvg target +161% vs current price
Analyst price target
~12-month · 6 analysts$29.17average target+161.0% vs now
Now $11.18
Low $4.00High $75.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$527.8M
52-wk high
$12.19
52-wk low
$4.19
50-day avg
$8.66
200-day avg
$6.82
Trailing P/E
—